Xilio Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
Xilio Therapeutics, Inc. filed a Form 8-K reporting the results of its 2022 annual meeting of stockholders held on June 9, 2022. The company is a Delaware corporation headquartered in Waltham, Massachusetts, and its common stock trades on Nasdaq under the symbol XLO.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Changes and Meeting Results
- Director elections: René Russo, Pharm.D. and Sara Bonstein were elected as Class I directors for three-year terms expiring at the 2025 annual meeting.
- René Russo: 20,085,672 votes for, 288,051 votes withheld, and 1,010,384 broker non-votes.
- Sara Bonstein: 20,237,758 votes for, 135,965 votes withheld, and 1,010,384 broker non-votes.
- Independent auditor: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 21,382,138 votes for, 1,233 against, and 736 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, new risk disclosures, contingencies, or unusual financial items. It identifies no material changes to the company’s business beyond the reported governance actions.
Investor Verification Items
- Verify the three-year terms and committee or governance responsibilities of the newly elected directors.
- Confirm Ernst & Young LLP’s appointment and review subsequent filings for any changes in auditor status.
- Review the company’s periodic reports for financial condition, cash runway, development progress, and other operating information not included in this 8-K.